Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active Target

Journal of the American College of Surgeons

Volumn 208, Issue 5, 2009, Pages 781-787

  Witkiewicz, Agnieszka K ^a   Costantino, Christina L ^a   Metz, Richard ^c   Muller, Alexander J ^c   Prendergast, George C ^a,c   Yeo, Charles J ^a   Brody, Jonathan R ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO 1 METHYLTRYPTOPHAN; DIOXYGENASE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE 2; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DNA POLYMORPHISM; GENE; GENE EXPRESSION; GENE TARGETING; GENOTYPE; HUMAN; HUMAN CELL; IDO2 GENE; IMMUNODETECTION; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; GENOTYPE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; PANCREATIC NEOPLASMS; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; UP-REGULATION;

EID: 64949113986     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2008.12.018     Document Type: Article

References (24)

1. Jones S., Zhang X., Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008) 1801-1806
2. Kennedy E.P., and Yeo C.J. The case for routine use of adjuvant therapy in pancreatic cancer. J Surg Oncol 95 (2007) 597-603
3. Winter J.M., Cameron J.L., Campbell K.A., et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10 (2006) 1199-1210 discussion 210-211
4. Zitvogel L., Tesniere A., and Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6 (2006) 715-727
5. Witkiewicz A., Williams T.K., Cozzitorto J., et al. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg 206 (2008) 849-854 discussion 854-856
6. Uyttenhove C., Pilotte L., Theate I., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9 (2003) 1269-1274
7. Colombo M.P., and Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 7 (2007) 880-887
8. Fallarino F., Grohmann U., You S., et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176 (2006) 6752-6761
9. Hou D.Y., Muller A.J., Sharma M.D., et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67 (2007) 792-801
10. Metz R., Duhadaway J.B., Kamasani U., et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 67 (2007) 7082-7087
11. Muller A.J., DuHadaway J.B., Donover P.S., et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11 (2005) 312-319
12. Munn D.H., and Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117 (2007) 1147-1154
13. Prendergast G.C. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27 (2008) 3889-3900
14. Muller A.J., and Prendergast G.C. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 7 (2007) 31-40
15. Muller A.J., Malachowski W.P., and Prendergast G.C. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets 9 (2005) 831-849
16. Brody J.R., Calhoun E.S., Gallmeier E., et al. Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media. Biotechniques 37 (2004) 598 600, 602
17. Brandacher G., Perathoner A., Ladurner R., et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12 (2006) 1144-1151
18. Pfefferkorn E.R. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA 81 (1984) 908-912
19. Yasui H., Takai K., Yoshida R., and Hayaishi O. Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. Proc Natl Acad Sci USA 83 (1986) 6622-6626
20. Calhoun E.S., Hucl T., Gallmeier E., et al. Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res 66 (2006) 7920-7928
21. Iacobuzio-Donahue C.A., van der Heijden M.S., Baumgartner M.R., et al. Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res 64 (2004) 871-875
22. Showalter S.L., Showalter T.N., Witkiewicz A., et al. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?. Cancer Biol Ther 7 (2008) 986-994
23. Laheru D., and Jaffee E.M. Immunotherapy for pancreatic cancer-science driving clinical progress. Nat Rev Cancer 5 (2005) 459-467
24. Muller A.J., and Prendergast G.C. Marrying immunotherapy with chemotherapy: why say IDO?. Cancer Res 65 (2005) 8065-8068